TAAV Biomanufacturing Solutions
Enzymatic DNA Production
Enzymatic DNA Production
neDNA™: Enzymatic DNA for rAAV Production
We are a CDMO working with biopharma companies, research centers and entities developing programs based on AAV-based gene therapies.
neDNA™: Discover TAAV produced enzymatic DNA
An alternative to plasmids for AAV production
We provide the first option for critical starting material for AAV production. Designed to transform and accelerate the traditional gene therapy development timelines.
Our goal
As individuals,
we dream
about future.
As scientists, we have
the chance to make
history.
Together, we have the
power to make it
happen.
Your AAV production starts now! We work in a uniquely collaborative industry that can make the world a better place. Let’s make it happen together.
Your rAAV manufacturing starts now. We work in a uniquely collaborative industry that can make the world a better place. Let’s make it happen together.
Led by Science. Inspired by People.
We are a highly innovative
company.
Our solution opens the door to a new area for gene therapy development. This innovation can be only understood by the power of science. But science needs hands. Science needs people committed to the future and passionate to change for better outcomes. We are aimed at changing patients’ lives: this is what inspire us.
We are an innovative life sciences company with the unique purpose of improving people’s lives. This is what inspire us.
Latest news:
Advanced Therapies Week
Nadja Andrade, Business Development Manager at TAAV, will be attending next Advanced Therapies Week (Phacilitate) in
Sebastián Almeida, New Biomanufacturing Director
San Sebastian, 20 October 2023. TAAV Biomanufacturing Solutions is pleased to announce the appointment of Sebastián
Poster: neDNA™, a Robust and High-Quality DNA Supply for rAAV Manufacturing
Download here the poster.
ESGCT 2023
We are proud of being a Silver Sponsor of the ESGCT 2023, the European Society of
Meeting on the MESA 2023
We are Silver Sponsor of the Alliance for Regenerative Medicine’s 2023 Cell and Gene Meeting on